Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction

Michael A. Nauck and David A. D'Alessio

Abstract

Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. Five clinical trials in type 2-diabetic subjects (SURPASS 1–5) have shown that tirzepatide at 5–15 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.4–11.7 kg) by amounts unprecedented for a single agent. A sizable proportion of patients (23.0 to 62.4%) reached an HbA1c of < 5.7% (which is the upper limit of the normal range indicating normoglycaemia), and 20.7 to 68.4% lost more than 10% of their baseline body weight. Tirzepatide was significantly more effective in reducing HbA1c and body weight than the selective GLP-1 RA semaglutide (1.0 mg per week), and titrated basal insulin. Adverse events related to tirzepatide were similar to what has been reported for selective GLP-1-RA, mainly nausea, vomiting, diarrhoea, and constipation, that were more common at higher doses. Cardiovascular events have been adjudicated across the whole study program, and MACE-4 (nonfatal myocardial infarction, non-fatal stroke, cardiovascular death and hospital admission for angina) events tended to be reduced over up to a 2 year-period, albeit with low numbers of events. For none of the cardiovascular events analysed (MACE-4, or its components) was a hazard ratio > 1.0 vs. pooled comparators found in a meta-analysis covering the whole clinical trial program, and the upper bounds of the confidence intervals for MACE were < 1.3, fulfilling conventional definitions of cardiovascular safety. Tirzepatide was found to improve insulin sensitivity and insulin secretory responses to a greater extent than semaglutide, and this was associated with lower prandial insulin and glucagon concentrations. Both drugs caused similar reductions in appetite, although tirzepatide caused greater weight loss. While the clinical effects of tirzepatide have been very encouraging, important questions remain as to the mechanism of action. While GIP reduces food intake and body weight in rodents, these effects have not been demonstrated in humans. Moreover, it remains to be shown that GIPR agonism can improve insulin secretion in type 2 diabetic patients who have been noted in previous studies to be unresponsive to GIP. Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1 RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.
The concept of co-agonists: molecules with effects on more than one peptide hormone receptor

The redundancy of the system to regulate food intake and body weight led to suggestions that multiple signaling pathways would need to be targeted for effective medical treatment of obesity [1]. Proof-of-concept studies were reported using simultaneous administration of peptides, e.g. leptin and amylin, to cause greater weight loss in rodent models [2]. In 2009, Day and colleagues reported the development of novel peptides engineered to agonize both the GLP-1 and glucagon receptors (GLP-1R and GCGR; [3]). The rationale for these agents was that combining the satiety effects of GLP-1 signaling with purported effects of glucagon to increase energy expenditure would lead to a more effective weight loss agent. In fact, this was demonstrated quite convincingly in obese mice, with some variability in effect depending on the relative balance of potency at the GLP-1R and GCGR. Of perhaps greater importance was the establishment of the process of iterative chemical refinement as a means of modifying the amino acid sequence of a known peptide to add agonism for multiple receptors [4]. Using this model an obvious strategy was to combine activity for GLP-1 with that of glucose-dependent insulinotropic polypeptide (GIP) to treat diabetes. Together GLP-1 and GIP account for the bulk of the incretin effect, a physiologic system evolved to augment insulin secretion following the ingestion of nutrients [5]. Both the GLP-1R and the GIP receptor (GIPR) are expressed on pancreatic β-cells and activation of these in the context of even modest elevations of blood glucose potently stimulate insulin secretion [6]. Activation of the GLP-1R lowers blood glucose in persons with type 2 diabetes while the GIPR is much less effective for this [7, 8]. Nonetheless, an engineered peptide with activity at both the GIPR and GLP-1R was more effective at reducing body weight and blood glucose in obese mice than a selective GLP-1R agonist (GLP-1RA) [9]. This compound was also superior to a GLP-1RA for stimulating insulin secretion in non-human primates, and reduced blood glucose in humans with diabetes. While the insulinoimotropic properties of a GIPR/GLP-1R co-agonist were expected, the effects on food intake and weight loss were not. However, recent work in rodents has demonstrated that the GIPR is expressed on neurons in the arcuate nucleus and other parts of the hypothalamus [10], and their activation reduces food intake and body weight [11], in particular when co-administered with GLP-1 [12]. This initial work, and other studies, heralded the development of a number of different multi-receptor peptides that have become the latest advances in therapeutics of diabetes and obesity.

Methodological details
This review is based primarily on information from preclinical studies in animal models and clinical trials in humans; a secondary analysis of the trial data has been included to highlight specific points. For this purpose, a PubMed literature search was performed using EndNote X7.1 (www.endnote.com), using the search terms “tirzepatide”, “LY3298176 “, ”dual GIP/GLP-1” and “GIP/GLP-1 receptor co-agonist”. Data in Tables 1 and 2 were taken from publications of phase 2 (GPWB) and 3 (SURPASS 1–5) trials. Data presented as Fig. 1 (molecular structure of tirzepatide and its relationship to GIP, GLP-1, and exendin–4) have been adopted from publications quoted in the respective legend. Data presented as Fig. 2 were taken from Coscun et al. 2018 [13]. Data presented as Fig. 3 have been taken from publications of phase 2 (GPWB) [14] and phase 3 (SURPASS 1–5) trials [15–19], strictly presenting the treatment estimand (or, in the case of GPWB, a Bayesian analysis according to a modified intention-to-treat approach excluding data gathered post-rescue, which is most similar to the treatment estimand, but, however, does not exclude data after treatment discontinuation). Data presented as Fig. 4 are redrawn from the SURPASS-4 publication [18] and from a publication summarizing cardiovascular events across the tirzepatide clinical trial program [20]. Dose–response relationships presented as Additional file 1: Figures S1, S2, S3 have been re-analyzed for the present manuscript from published data of the SURPASS 1–5 trials [15–19], uniformly extracting data according to the efficacy estimand (excluding data after drug discontinuation or rescue therapy), i.e. in patients precisely on their randomized treatment, as appropriate for the analysis of a dose–response relationship. For the 5, 10, and 15 mg per week doses, weighted means and pooled standard errors of the mean (derived from pooled standard deviations and the number of patients in each trial) were calculated and displayed and compared by analysis of variance. This analysis assumes comparable dose response relationships across the distinct cohorts in the SURPASS studies. The degree of homogeneity was estimated by calculating q and I² statistics. For categorial variables (proportion of patients with target achievement and adverse events), 95% confidence intervals were calculated and displayed and compared by χ² tests.

Keywords: GLP-1 receptor agonists, GIP/GLP-1 receptor co-agonists, Glycemic control, HbA1c, Body weight, Type 2 diabetes
### Table 1  Baseline characteristics of patients with type 2 diabetes participating in clinical trials (phase 2 and 3) with the GIP/GLP-1 receptor co-agonist tirzepatide

| Parameter                  | Unit | Phase 2 (GPGB) | SURPASS-1 [15] | SURPASS-2 [16] | SURPASS-3 [17] | SURPASS-4 [18] | SURPASS-5 [19] |
|----------------------------|------|----------------|----------------|----------------|----------------|----------------|----------------|
| Comparator(s)              |      | Placebo, dulaglutide 1.5 mg | Placebo | Semaglutide 1 mg | Insulin degludec | Insulin glargine | Placebo        |
| Study duration             | Weeks| 26             | 40             | 40             | 52             | 52/104*        |                |
| Overall patient number     |      | 316**          | 478            | 1878           | 2874           | 1995           | 475            |
| Background medication      |      | None (monotherapy⁷) | Metformin | Metformin± SGLT-2 inhibitor | Metformin± SGLT-2 inhibitor or sulfonylurea (alone or in combination) | Insulin glargine ± metformin |
| Age                        | Years| 57.2           | 54.1           | 56.6           | 57.4           | 63.6           | 60.7           |
| Female                     | %    | 47.3           | 48             | 53             | 56             | 38             | 44             |
| Duration of diabetes       | years| 8.7            | 4.7            | 8.6            | 8.4            | 10.5           | 13.3           |
| HbA₁c                      | %    | 8.12           | 7.94           | 8.28           | 8.17           | 8.52           | 8.32           |
| Fasting plasma glucose     | mmol/l| 9.4         | 8.5            | 9.6            | 9.4            | 9.5            | 9.0            |
| Body-mass-index            | kg/m²| 32.5           | 31.9           | 34.2           | 33.5           | 32.6           | 33.4           |
| Receiving metformin        | %    | 90.5           | –              | 100            | 100            | 95             | 82.5           |
| Receiving SGLT-2 inhibitor | %    | –              | –              | –              | 32             | 25             | –              |
| Receiving sulfonylurea     | %    | –              | –              | –              | –              | 54             | –              |
| eGFR                       | ml/min per 1.73 m² | 92.7          | 94.1           | 960            | 94.1           | 81.3           | 85.5           |

### Table 2  “Gastro-intestinal” adverse events reported in clinical trials comparing tirzepatide (5, 10, and 15 mg pre week) with selective GLP-1 receptor agonists (dulaglutide 1.5 mg/week and semaglutide 1.0 mg per week)

| Study                  | Phase 2 (GPGB), 26 weeks [14] | SURPASS-2, 40 weeks [16] |
|------------------------|--------------------------------|--------------------------|
| Agent                  | Tirzepatide | Dulaglutide | Tirzepatide | Semaglutide |
| Dose                   | 5 mg  | 10 mg  | 15 mg  | 1.5 mg  | 5 mg  | 10 mg  | 15 mg  | 1 mg  |
| Patient numbers per arm | 55     | 51     | 53     | 54     | 470   | 469    | 470    | 469    |
| Effectiveness          |        |        |        |        |        |        |        |        |
| HbA₁c reduction vs. baseline [%]* | −1.6  | −2.0  | −2.4  | −1.1  | −2.0  | −2.2  | −2.3  | −1.9  |
| Body weight reduction vs. baseline [kg]†    | −4.8  | −8.7  | −11.3 | −2.7  | −7.8  | −10.3 | −12.4 | −7.8  |
| Adverse events         |        |        |        |        |        |        |        |        |
| Nausea                 | 20.0   | 21.6   | 39.6   | 29.6   | 17.4  | 19.2   | 22.1   | 17.9   |
| Vomiting               | 7.3    | 15.7   | 26.4   | 9.3    | 5.7   | 8.5    | 9.8    | 8.3    |
| Diarrhoea              | 23.6   | 23.5   | 32.1   | 16.7   | 13.2  | 16.4   | 13.8   | 11.5   |
| Constipation           | 3.6    | 11.8   | 3.8    | 5.6    | 6.8   | 4.5    | 4.5    | 5.8    |
| Any “gastro-intestinal” adverse event | 32.7  | 51.0   | 66.0   | 42.6   | 40.0  | 46.1   | 44.9   | 41.2   |
| Adverse event leading to treatment discontinuation | 9.1    | 5.9    | 24.5   | 11.1   | 6.0   | 8.5    | 8.5    | 4.1    |
Tirzepatide (LY3298176): pharmacologic development of a unimolecular dual GLP-1R/GIPR co-agonist

Tirzepatide was one of several single molecule GIPR and GLP-1R agonists developed after the early work in multi-receptor peptides. It is a 39 amino acid linear peptide, similar in size to GIP and GLP-1, which are related hormones both belonging to the secretin family of gut peptides. The starting amino acid sequence was that of human GIP and tirzepatide retains 9 homologous amino acids from this peptide as well as 10 amino acids shared by GIP and GLP-1. Four amino acids correspond to the same position in the GLP-1 molecule, and 10 amino-terminal amino acids are identical to those in the sequence of exendin-4 (a peptide from the saliva of a lizard called Heloderma suspectum, later becoming exenatide, the first GLP-1 RA [21]). In addition, amino-iso-butyric acid residues are found in positions 2 (a recognition site for dipeptidyl peptidase-4) and 13, and three amino acid positions are unique to tirzepatide. An (AEEA)2-gamma Glu-C20 diacid is attached to the lysine residue in position 20, which promotes binding to albumin, and is essential in promoting a long duration of action (like in liraglutide and semaglutide as well as in long-acting insulin analogues degludec and icodex). The sequence of tirzepatide and the origin of each amino acid within the sequence is shown as Fig. 1.

In pancreatic β-cells, tirzepatide stimulates cAMP generation much like a combination of GIP and GLP-1 [13]. The dose–response relationship for cAMP production in human embryonic kidney cells (HEK293) transfected with human incretin receptors indicates similar activation of GIPR receptors as native GIP, with lower potency on GLP-1R compared to endogenous GLP-1 [13]. Tracer displacement studies as well as cAMP generation studies show binding to and stimulation of GIP receptors
similar to native GIP, whereas binding and effects at the GLP-1 receptor are less than native GLP-1 [13]. In keeping with the data in transfected cells, cAMP production in differentiated human adipocytes with tirzepatide follows the same dose–response relationship as for human GIP [13]. Overall tirzepatide seems to preferentially activate GIP receptors over GLP-1 receptors in isolated cell systems with high-grade expression of GIP and GLP-1 receptors. Structural prerequisites explaining receptor bifunctionality as well as the preferential binding to and activation of GIP relative to GLP-1 receptors have been extensively studied [25]. Concentrations of tirzepatide, GIP and GLP-1 leading to half maximal tracer displacement (binding affinity) and to half-maximal cAMP generation reported in Coskun et al. 2018 [13] are displayed in Fig. 2. In murine pancreatic islets lacking GLP-1 receptors, tirzepatide-stimulated insulin secretion was completely blocked by a GIPR antagonist, while in islets from GIP receptor knock-out mice, tirzepatide-stimulated insulin secretion is completely blocked by GLP-1R antagonism [13]. In mice with diet-induced obesity, tirzepatide reduced both food intake and body weight significantly better than did semaglutide, the most effective selective GLP-1 RA available [13].

In human subjects, international phase 1 studies indicated a linear relationship between the dose of tirzepatide and peak circulating concentrations (C\text{max}), a time from injection to C\text{max} of 1–2 days, and an elimination half-life of approximately 5 days [13]. In patients with type 2 diabetes, over 29 days, body weight was reduced by up to 3 kg, fasting plasma glucose was reduced by up to 3 mmol/l, plasma glucose following an oral glucose load was dose-dependently reduced, while insulin secretory responses were dose-dependently increased. Similar pharmacokinetic and initial pharmacodynamic data were collected in Japanese subjects with type 2 diabetes [26]. Neither renal functional impairment [27] nor compromised liver function [28] change the pharmacokinetic behavior of tirzepatide. Based on these findings, the dosage of tirzepatide will likely not have to be changed in chronic kidney disease or with reduced liver function, but dedicated clinical studies in such patients are not yet available.

**Fig. 2** Binding affinity of GIP, GLP-1, and the dual (GIP and GLP-1 receptor) co-agonist tirzepatide (formerly named LY3298176) to human embryonic kidney (HEK 293) cells transfected with human GIP and GLP-1 receptors, and potency in stimulating cyclic adenosine mono-phosphate (cAMP) accumulation. Data have been taken from Coskun et al. 2018 [13] and are expressed as EC50 (effective concentration resulting in half-maximal stimulation) or K\text{i} (inhibitory constant, leading to half-maximal displacement of tracer)

Tirzepatide phase 2 study in type 2 diabetes: optimization of initial up-titration schedule and definition of effective and tolerable dose range

In the primary phase 2 trial [14], doses of tirzepatide from 1 to 15 mg per week were compared to placebo and the selective GLP-1 receptor agonist dulaglutide, 1.5 mg per week. Baseline characteristics of type 2 diabetes subjects are shown as part of Table 1. Tirzepatide at doses of 5, 10, and 15 mg was more effective than dulaglutide (1.5 mg) in reducing HbA1c (by up to 2.4% from a baseline of 8.12%). Notably, 30.2% of the patients treated with 15 mg per week reached an HbA1c < 5.7% (corresponding to the normal range in healthy subjects; Fig. 3) [14]. Likewise, tirzepatide at doses of 5, 10, and 15 mg was more effective than dulaglutide (1.5 mg) in reducing body weight (by up to 11.3 kg from a baseline of 91.2 kg; Fig. 3). Notably, 24.5% of patients treated with 15 mg per week reached a body weight reduction of ≥15% [14]. Nausea, diarrhoea, and vomiting were identified as the most prominent adverse events (Table 2). Since with the 15 mg per week dose of tirzepatide, 18 out of 53 (34.0%) subjects in the initial phase 2 trial discontinued treatment (13 or 24.5% because of adverse events), slower and more cautious initial up-titration schedules were the dedicated focus of a second phase 2 trial [29], which resulted in a much-reduced discontinuation rate (e.g., 1 out of 28 or 3.6% randomized to tirzepatide 15 mg discontinued because of adverse events). Essential elements of this better tolerated regime of introducing tirzepatide treatment was carried on into phase 3 studies.
Fig. 3  Efficacy of tirzepatide in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 to 5; [15–19]) clinical trials, all according to the treatment estimand (SURPASS 1–5) or by Bayesian modified intention-to-treat analysis without considering data acquired post-rescue (GPWB). The upper row of panels depicts effects on HbA1c (reduction vs. baseline). The lower row of panels shows effects on body weight (reduction vs. baseline). Asterisks (*) indicate a significant difference (p < 0.05) vs. the respective comparator. Comparators were placebo and dulaglutide (1.5 mg per week) in phase 2 (GPGB), placebo (grey; SURPASS-1 and -5), semaglutide 1.0 mg (orange; SURPASS-2), basal insulin degludec (darker brown; SURPASS-3) and basal insulin glargine U100 (lighter brown; SURPASS-4). Patient numbers per arm are presented in the bottom of the lower panels.

Fig. 4  Effects of tirzepatide on adjudicated cardiovascular events in SURPASS-4 [18] (A), a clinical trial recruiting subjects at high risk for cardiovascular events, and across the clinical trial program (phases 2 and 3) for tirzepatide [20] (B). MACE: Major adverse cardiovascular events. The line of identity (red, dashed) indicates an equal risk for CV events for tirzepatide and comparator(s). The blue, dashed line marks a hazard ratio of 1.3. An upper bound of the confidence interval for composite endpoints (MACE-3 and MACE-4, but not for individual endpoints) below 1.3 conventionally is interpreted as indicating a cardiovascular risk, which is not significantly elevated in comparison to the comparator(s). Comparators include placebo, insulin degludec, insulin glargine, dulaglutide 1.5 mg/week, and semaglutide 1.0 mg/week (GLP-1 receptor agonists). The numbers of patients at risk and the numbers of events observed are presented. The asterisk indicates a significant difference indirectly inferred from the 95% confidence interval completely being below the line of identity (≠ 1)
The SURPASS program in type 2 diabetes: proof of effectiveness and of safety/tolerability

The pivotal clinical trial program designed to prove therapeutic effectiveness (glycaemic control and body weight reduction) and safety/tolerability for the treatment of patients with type 2 diabetes has been named the SURPASS program, encompassing trials SURPASS 1–6, SURPASS-J mono and combo, respectively, in Japanese populations, SURPASS-AP in Asian-Pacific patients, and SURPASS CVOT, a dedicated cardiovascular outcomes trial which is ongoing and will report in 2024 [30]. These trials share common features: Tirzepatide treatment is studied at three final doses (5, 10, 15 mg per week), initiating treatment at 2.5 mg, and increasing the dose every 4 weeks. Some SURPASS trials compare tirzepatide to placebo treatment, others use active comparators like semaglutide, a selective GLP-1 receptor agonist, or the basal insulin preparations, insulins degludec or glargine (see Table 1). SURPASS-CVOT has a different design from the effectiveness/safety/tolerability trials in that it attempts to reach the maximum tolerated dose in every patient, and because it is a two-arm study, using dulaglutide (1.5 mg per week or highest tolerated dose) as comparator [30].

Across the doses ranging from 5 to 15 mg of tirzepatide per week, HbA1c was reduced in SURPASS 1–5 by between 1.69 to 2.58% (Fig. 3), with approximately 24–30 weeks of treatment to reach a new plateau of HbA1c and fasting plasma glucose [15–19]. Among subjects treated with tirzepatide, 81.0–92.9% reached an HbA1c < 7.0%, 66.0–86.0% reached an HbA1c < 6.5%, and 23.0–62.4% reached an HbA1c < 5.7%; the latter corresponding to an accepted correlate of normal glucose tolerance [15–19]. Fasting plasma glucose was reduced in SURPASS 1–5 by between 2.4 and 3.5 mmol/l [15–19]. Across the doses ranging from 5 to 15 mg of tirzepatide per week, body weight was reduced in SURPASS 1–5 by between 5.4 to 11.7 kg (Fig. 3) [15–19]. Remarkably, a plateau was not reached in studies with a duration shorter than 52 weeks [15, 16, 19], and it may take more than a year to achieve a new steady-state body weight after initiating tirzepatide treatment [18].

Tirzepatide at all three doses proved to be significantly more effective than placebo [15, 19], both with respect to parameters of glycaemic control and body weight reduction (Fig. 3). More remarkably, tirzepatide was significantly more efficacious compared to titrated basal insulins degludec [17] and glargine [18] (Fig. 3). In these trials, tirzepatide at higher doses was at least as effective as basal insulin preparations in controlling fasting plasma glucose. In previous studies of GLP-1RAs, only semaglutide [31], the most potent compound in this class [32, 33], had a similar effect. Predictably, post-prandial glycaemic excursions were better controlled with tirzepatide than with basal insulin [17, 18]. The most remarkable finding, however, is the substantially better efficacy (regarding both HbA1c and body weight reductions) when compared to 1.0 mg semaglutide per week (the standard dose used in most type 2 diabetes trials [34]) (Fig. 3). It is reasonable to infer from this treatment difference that GIPR agonism contributed significantly to the overall effectiveness of tirzepatide.

For a closer look into the dose–response relationships comparing 5, 10, and 15 mg per week of tirzepatide, we refer to a meta-analysis of results reported from SURPASS-1–5 (Additional file 1: Figures. S1, S2, S3). There were significant dose-dependent reductions of HbA1c and body weight from the pretreatment baseline with each dose step from 5 to 15 mg of tirzepatide. This dose-dependency was also seen with fasting glucose, although the trend did not reach statistical significance (Additional file 1: Figure. S1). Similar dose proportionality was seen for HbA1c targets, with higher doses leading to an increased percentage of patients achieving values <7.0%, ≤6.5%, or ≤5.7% (Additional file 1: Figure S2). Dose–response relationships were steepest for the HbA1c ≤0.57% target, and shallowest for the HbA1c < 7.0% target. Despite the overall robust treatment effects, it is remarkable that 11.1% of treated subjects did not reach this standard glycemic target even with the highest dose of tirzepatide (compare Additional file 1: Figure S2, details not shown).

The relative reductions in HbA1c and body weight observed with doses of 5, 10 and 15 mg per week of tirzepatide were similar among the 5 SURPASS trials (Fig. 3). Accordingly, post hoc analyses of the SURPASS clinical trial program indicate that the reduction in HbA1c is independent of age [35], duration of diabetes [36], or baseline HbA1c ≤vs. > 8.5% [37]—the latter results showing meaningful reductions in both subgroups, but with higher baseline HbA1c predicting greater reductions. With respect to body weight, a higher baseline body-mass-index is a predictor of absolute weight reduction, albeit with substantial body weight loss even in those with a BMI < 27 kg/m² [38]. Female vs. male sex does not influence body weight reduction with tirzepatide treatment [39]. Another notable finding from the SURPASS trials is a significant correlation between weight reduction achieved with tirzepatide and the reduction in HbA1c indicating that greater weight loss in the range achievable with tirzepatide has a substantial impact on glycemic control [40], as shown for most but not all the SURPASS trials and doses tested (it was not shown for SURPASS 1 and for 10 mg and 15 mg doses in SURPASS-5, i.e. the clinical studies with smaller patient numbers; Table 1; Fig. 3). No such association has been
Cardiovascular risk factors and safety

Like selective GLP-1 receptor agonists, tirzepatide improved a number of cardiovascular risk factors. In blood samples analyzed from the phase 2 (GPGB) study, triglycerides and the constituent, apolipoprotein C-III, were dose-dependently reduced, significantly more than with dulaglutide 1.5 mg per week [43]. LDL cholesterol and its constituent, apolipoprotein B, were reduced with tirzepatide, but not more than with dulaglutide [43]. In general, large triglyceride-rich lipoproteins were reduced as were small low-density lipoproteins, while changes with dulaglutide treatment were not significant [43]. In keeping with these changes, total diacylglycerols were dose-dependently reduced with tirzepatide, more than with dulaglutide, as were total phosphatidylethanolamines and phosphatidylcholines [44]. Circulating lipoprotein lipase (in the absence of heparin injection) was increased by tirzepatide treatment, more than with dulaglutide [43]. Circulating concentrations of branched-chain amino acids (leucine, isoleucine, and valine) and branched-chain ketoacids were dose-dependently reduced with tirzepatide, while dulaglutide had no significant effect [44]. Concentrations of 2-hydroxybutyric acid were reduced more with tirzepatide than with dulaglutide [44]. In the SURPASS-1 and -2 studies, significant reductions in triglycerides (by 18.5 to 24.8%), in LDL cholesterol (by 5.2 to 12.4%), and in VLDL cholesterol (by 17.5 to 23.7%), as well as a significant increase of HDL cholesterol (by 3.2–7.9%) were confirmed [15, 16]. Changes in triglycerides and VLDL cholesterol clearly exceeded those elicited by semaglutide 1.0 mg/week [16], Systolic blood pressure was reduced in all SURPASS trials in a dose-dependent manner, by approximately 5–6 mmHg [15–19], more substantially than with semaglutide (by 3.6 mmHg on average) in SURPASS-2 [16]. Inflamatory markers like C-reactive protein (but not interleukin-1) and circulating adhesion molecules like ICAM-1 (but not VCAM-1) were reduced by tirzepatide treatment [45].

The effect of tirzepatide treatment on cardiovascular events has been studied in SURPASS-4, a trial recruiting subjects with known coronary, peripheral arterial, or cerebrovascular disease, or who were at high risk for these, i.e. age > 50 years with either chronic kidney disease and an eGFR of less than 60 ml/min per 1.73 m² or history of congestive heart failure (NY Heart Association Class II or III). In addition, SURPASS-4 had the longest duration of the completed studies phase 3 studies tirzepatide trials (Table 1); SURPASS-CVOT will have a considerably longer duration. Figure 4 shows the results of SURPASS-4 by tirzepatide dose as well as for all doses pooled, compared to insulin glargine treatment. No tirzepatide dose numerically increased the risk for cardiovascular events. For subjects treated with the highest dose of tirzepatide (15 mg per week), the risk to develop any major adverse cardiovascular event (MACE-4 composed of myocardial infarction, stroke, hospitalization for angina, and all-cause death) was estimated at 0.50 (0.26–0.95). However, this was based on only 11 events in the tirzepatide 15 mg/week group (and 62 events with insulin glargine treatment; Fig. 4A). In addition to the results from SURPASS 4, which was designed to provide preliminary evidence for the cardiovascular safety of tirzepatide, a separate analysis pooling all the clinical trials with tirzepatide was used to generate a pre-specified estimate of cardiovascular events [20] (Table 1). Relative to comparators, the risk for any of the commonly used cardiovascular end points was estimated to be below 1.0, and for both MACE-4 and MACE-3 (myocardial infarction, stroke, and all-cause death), the upper bounds of the confidence interval calculated around the hazard ratio were decidedly < 1.3 (Fig. 4B). Thus, these data suffice as preliminary evidence of cardiovascular safety for tirzepatide according to US Food and Drug Administration guidance. Results in subgroups defined by sex, age, baseline HbA1c, ethnic composition, country of origin, and SGLT-2 inhibitor use at baseline did not differ from overall results. A dedicated clinical trial is being performed to provide definite answers regarding the cardiovascular safety and potential
cardiovascular benefits of tirzepatide (SURPASS CVOT; https://ClinicalTrials.gov/ct2/show/NCT04255433) [30]. In this study tirzepatide will be compared to dulaglutide, a selective GLP-1 RA with proven cardiovascular benefits [46].

Adverse events reported with tirzepatide (dual GIP/GLP-1 receptor co-agonist)
In clinical trials employing tirzepatide, nausea, vomiting, diarrhoea, and constipation were the main side effects reported. These “gastrointestinal” side effects appear to be qualitatively similar to those reported in clinical studies with selective GLP-1 RAs, and display some dose-dependency (Additional file 1: Figure S3). Therefore, in quantitative terms, a comparison to selective GLP-1 RAs is of particular interest. Table 2 presents the proportion of patients reporting nausea, vomiting, diarrhoea, constipation, or any gastrointestinal adverse event in studies comparing tirzepatide at 5, 10, or 15 mg per week to dulaglutide (1.5 mg per week) [14] or semaglutide (1 mg/week) [16]. As shown in Table 2, higher doses of tirzepatide are associated with more of these side effects (see also Additional file 1: Figure S3).

However, in both studies, there was a trend for numerically greater effectiveness of tirzepatide (5 mg per week) as compared to dulaglutide (phase 2 study; GPWB) or semaglutide (SURPASS-2), with respect to improving glycaemic control (HbA1c) and reducing body weight, but fewer patients reported “gastrointestinal” side effects as compared to those treated with dulaglutide or semaglutide. This may indicate that for a given efficacy, tirzepatide elicits less gastrointestinal adverse events than do selective GLP-1 RAs. Along these lines, GIPR agonism in animal experiments had the ability to reduce GLP-1-induced nausea and vomiting, or an equivalent behaviour [47, 48]. The availability of three doses of tirzepatide provides the flexibility to find an individual optimum relating effectiveness and tolerability.

Mechanisms of action of tirzepatide (dual GIP/GLP-1 receptor co-agonist), with particular emphasis of differences to selective GLP-1 receptor agonists
Given the impressive results of the tirzepatide clinical trials, understanding pharmacologic mechanisms of action is likely to provide insight into the pathogenesis and correction of diabetes and obesity. Moreover, differentiating a GIP/GLP-1 receptor co-agonist from a selective GLP-1 receptor agonist has implications for the broader scope of multi-receptor targeting in metabolic disease. Are there footprints of GIP receptor agonism in the studies to date? An experiment based on the general protocol of the SURPASS-2 study, but including physiological outcomes, was recently reported. At baseline and after 28 weeks of treatment, Heise et al. performed a hyperinsulinaemic, euglycaemic clamp experiment to estimate insulin sensitivity, followed by a hyperglycaemic clamp (216 mg/dl;12.0 mmol/l) to estimate insulin secretory responses. On a second day of study, plasma glucose, insulin and glucagon responses were recorded following a mixed meal test with concurrent assessment of ratings (visual analogue scales) of hunger, satiety, prospective food consumption, and fullness; energy intake was measured on the occasion of an ad libitum meal [49, 50]. The clinical results of this trial mimicked the primary findings of SURPASS-2 with comparable HbA1c reduction and loss of body weight. Insulin sensitivity as measured by the glucose infusion rate needed to maintain euglycaemia rose by 65.7% with tirzepatide (as compared to 37.5% with semaglutide 1.0 mg). Thus, the rise in insulin sensitivity was 20.5% greater with tirzepatide as compared to semaglutide. Some of this effect is likely due to the difference in body weight reduction (average 11.2 kg with tirzepatide vs. 6.9 kg with semaglutide) [50], and in fact, the improvement in insulin sensitivity was related to the individual degree of body weight reduction. However, the slope of the regression line relating insulin sensitivity to amount of weight loss was significantly steeper for tirzepatide compared to semaglutide [49]. These results suggest that there may be weight-dependent and weight-independent components to the improvement in insulin sensitivity accompanying tirzepatide treatment, and that there is a greater improvement in insulin sensitivity per unit weight loss with tirzepatide as compared to semaglutide [49].

The meal tests indicated a significant reduction in fasting and post-meal plasma glucose concentrations with both tirzepatide and semaglutide compared with placebo treatment, and baseline-subtracted plasma glucose increments did not differ between the two drug treatments [50]. Meal-related insulin secretory responses were significantly smaller with tirzepatide compared to both semaglutide and placebo treatment [50], compatible with the improvements in insulin sensitivity. Meal-related rises in plasma glucagon were smaller with tirzepatide than with semaglutide, and substantially and significantly reduced vs. placebo treatment with both semaglutide and tirzepatide [50]. While appetite ratings and ad libitum energy intake were lower with semaglutide and tirzepatide treatment as compared to placebo, they did not differ significantly between the selective GLP-1 RA and the dual GIP/GLP-1 receptor co-agonist [49]. While the described findings help to explain some aspects of the clinical effectiveness of tirzepatide, it is not possible to discern from this experiment whether the distinct effects of tirzepatide relative to semaglutide are the result of GIPR signaling.
Animal studies have identified major effects of tirzepatide on insulin sensitivity in mice with diet-induced obesity [51]. Since, in the same study, a long-acting GIP also had marked effects on insulin sensitivity, an insulin-sensitizing effect of GIPR activation can be inferred. The insulin-sensitizing effect of tirzepatide appears to be relatively more potent in mice with diet-induced obesity [51] than in human subjects with type 2 diabetes [50]. Potential mechanisms include a reduction in ectopic, e.g., liver, pancreas and skeletal muscle, fat deposition, possibly mediated through preferential storage of triacyl glycerols in subcutaneous adipose tissue depots [52]. Details on the effect of GIP receptor agonism on adipose tissue are extensively discussed in Nauck et al. 2021 [53].

In studies of humans with type 2 diabetes, glycaemic control is generally better with tirzepatide than with selective GLP-1 RAs (dulaglutide [14], semaglutide [16]) coincident with a greater insulin response to glucose [50]. One explanation for these results is that GIPR agonism contributes to enhanced insulin secretion in tirzepatide treated patients. However, this conjecture is contrary to previous studies reporting very meager beta-cell stimulation in type 2 diabetic subjects receiving native GIP [7, 59] (Table 3), a deficit that may be due to specific defects in expression or function of GIP receptors, or to a general impairment of endocrine pancreatic ß-cells to respond to strong insulino tropic stimuli [71]. It is possible that GIPR agonism with tirzepatide is accentuated by the long exposure relative to the effects of acute treatments in older studies [7, 59]. Moreover, glucose lowering with 4 weeks of intensified insulin treatment partially restores the insulino tropic action of GIP (and GLP-1) [72], and this may also occur in response to the glycemic effects of several weeks of tirzepatide treatment. Co-stimulation of GLP-1 receptors may induce a similar phenomenon, especially since there are obvious interactions in the signaling pathways for GIP and GLP-1 [73, 74]. If GIPR agonism induced by tirzepatide treatment is responsible for enhanced ß-cell secretion, it is reasonable to assume a time-dependent process re-establishing GIP as an effective insulin secretagogue even in advanced type 2 diabetes. These possibilities require dedicated mechanistic studies to verify.

In rodents, hypothalamic neurons producing COMT [catechol-O-methyl transferase] and CART [cocaïne- and amphetamine-regulated transcript] are involved in the regulation of satiety and energy intake; these neurons also express GIP and/or GLP-1 receptors [75]. Selective stimulation of these neurons reduces food intake [75], but does not poten tiate the effects of concomitantly administered selective GLP-1 receptor agonists. Consistent with these observations, both intracerebroventricular and peripheral injections of a GIP receptor agonist reduce energy intake in rodents with diet-induced obesity or diabetes [11], effects that are abolished by genetic deletion of the GIPR. Such studies support a role for GIPR agonism to contribute to weight reduction with dual GIP/GLP-1 receptor co-agonists. However, based on currently available human studies (summarized in Table 3), this mechanism lacks experimental support. To wit, exogenous GIP, given at supraphysiologic doses, did not change ratings of appetite or ad libitum food intake in human subjects [69], whereas, in the same study, exogenous GLP-1 displayed robust effects on both. Surprisingly, combining GLP-1 and GIP led to a lesser suppression of appetite and energy intake compared to GLP-1 alone. Likewise, antagonizing endogenous GIP actions with the specific antagonist GIP (3–30 NH₃) did not change subjective measures of appetite, satiety, or prospective food consumption after ingesting a mixed meal [57].

Thus, human studies addressing a potential role of GIP in reducing appetite, energy intake, and body weight have produced discordant results from preclinical studies. However, the human studies with GIP done to date have used short-term (maximum 6 days) infusions of native GIP, which may not approximate the effects of tirzepatide with respect to pharmacokinetics, GIP receptor engagement, or interaction with stimulated GLP-1 receptors. Moreover, even in animal experiments, the question remains open as to whether GIP agonism or GIP antagonism is the better way to achieve body weight reduction [76]. In fact, GIP agonism has been proposed to cause desensitization of GIPR signaling and lead to a state of functional antagonism [77]. It is too early to conclude a species difference in this respect, and more science is necessary to align these contrasting findings and to clarify the role of GIP in the regulation of body weight in human subjects in particular.

**Upcoming indications beyond type 2 diabetes: obesity (without diabetes) and non-alcoholic fatty liver disease**

The dual GIP/GLP-1 receptor co-agonist combining agonism at both incretin hormones’ receptors (“twincretin”) was originally been designed as a novel treatment for type 2 diabetes. The highly effective reduction in body weight (Fig. 3) observed in type 2-diabetic patients with tirzepatide has shown the obvious potential in the treatment of obesity in the absence of type 2 diabetes. Recently, a dedicated obesity study has been published, which in quantitative terms shows even greater weight loss in the absence of diabetes. Jastreboff et al. reported reductions of 15 to 20.9% of initial body weight with 5 to 15 mg tirzepatide per week [78]. This was accompanied by changes in waist circumference (by up to 18.5 cm with the highest dose), in systolic (−7.2 mmHg) and diastolic (−4.8 mmHg) blood pressure, and in lipids [e.g., triglycerides − 24.8 mg/dl; HDL cholesterol + 8 mg/dl; VLDL cholesterol − 24.4 mg/dl]. The main adverse events reported were again nausea, diarrhoea, vomiting, and constipation [78]. The greater degree of weight loss in non-diabetic obese subjects may...
Table 3  Influence of GLP-1, GIP, their combination, and tirzepatide (dual GIP/GLP-1 receptor co-agonist) on determinants of glycaemic control and body weight in healthy and type 2-diabetic human subjects

| Parameter/Population studied | Previous findings regarding short-term exposure to GLP-1 | GIP | Combination of GLP-1 and GIP | Current findings with long-term exposure to Tirzepatide (dual GIP/GLP-1 receptor co-agonist) |
|------------------------------|--------------|----|-----------------------------|---------------------------------------------|
| Insulin secretion            |              |    |                             |                                             |
| Healthy subjects             | Glucose-dependent stimulation [54, 55]              | Glucose-dependent stimulation [55]       | Additive glucose-dependent stimulation [55–57] | Not studied                                  |
| Type 2 diabetes patients     | Largely preserved glucose-dependent stimulation [7, 58] | Much-reduced glucose-dependent stimulation (almost no effect) [7, 59] | Not different from effects of GLP-1 alone (negligible effects of GIP) [8] | Stimulated more than with selective GLP-1 RA semaglutide [50] (suggesting some effect of GIPR agonism) |
| Glucagon secretion           |              |    |                             |                                             |
| Healthy subjects             | Little effect at moderate hyperglycaemia [7], no effect at hypoglycaemia [60] | Stimulation (dependent on plasma glucose concentrations) [61] | Not studied | Not studied |
| Type 2 diabetes patients     | Suppression at moderate hyperglycaemia [7, 8]      | No significant effect at moderate hyperglycaemia [7, 8], stimulation at low plasma glucose [62] | No effect (i.e., the GLP-1-induced suppression is counteracted by concomitant exposure to GIP [8]) | Suppression (greater than suppression with selective GLP-1 RA semaglutide) [50] (suggesting some effect of GIPR agonism) |
| Insulin sensitivity          |              |    |                             |                                             |
| Healthy subjects             | No acute effects [63]                             | Not studied | Not studied | Not studied |
| Type 2 diabetes patients     | No acute effects [64]                             | Not studied | Not studied | Increased with long-term administration (accompanied by substantial weight loss), more than with the selective GLP-1 RA semaglutide [50] |
| Meal tolerance               |              |    |                             |                                             |
| Healthy subjects             | Not studied | Slightly worsened [66] (stimulation of glucagon) | Not studied | Not studied |
| Type 2 diabetes patients     | Improved [65] (mainly through deceleration of gastric emptying) | Not studied | Not studied | Not studied |
| Glycated haemoglobin (HbA1c) Type 2 diabetes patients | Reduced [67] | Not studied | Not studied | Greater reduction in fasting plasma glucose and HbA1c as compared to selective GLP-1 RAs (e.g., dulaglutide [14] or semaglutide [16]) |
| Appetite Healthy or non-diabetic obese subjects | Reduced (robust findings) [68] | Not changed [69] | Not changed [69] | Appetite reduced with tirzepatide and semaglutide (selective GLP-1 RA) to a similar degree [49] |
| Caloric intake (ad libitum meal) Healthy or non-diabetic obese subjects | Reduced (robust findings) [68, 70] | Not changed [69] | Less reduction compared to GLP-1 alone [69] | Similar reduction compared to selective GLP-1 RA semaglutide [49] |
| Energy expenditure Healthy or non-diabetic obese subjects | Not changed [69] | Not changed [69] | Not changed [69] | Not studied |
| Parameter/Population studied | Previous findings regarding short-term exposure to GLP-1 | GIP | Combination of GLP-1 and GIP | Current findings with long-term exposure to Tirzepatide (dual GIP/GLP-1 receptor co-agonist) |
|-----------------------------|---------------------------------------------------------|-----|-----------------------------|--------------------------------------------------------------------------------|
| Body weight                 | Reduced after 6 weeks of s.c. infusion [67]              | Not studied | Not studied | Substantial reduction (see Fig. 3; more than with selective GLP-1 RA semaglutide [50]) |
| Type 2 diabetes patients    |                                                         |     |                             |                                                                                   |

GLP-1 glucagon-like peptide-1, GIP glucose-dependent insulinotropic polypeptide, GIPR GIP receptor, RA receptor agonist, HbA1c glycated haemoglobin, fraction A1c
in part be explained by the fact that in diabetic subjects with relatively high baseline HbA1c, reducing plasma glucose concentrations triggers a reduction in glucosuria. Yki-Järvinen calculated an approximately 2 kg weight difference for a reduction in HbA1c by 1.0% through the influence on caloric losses via glucosuria [79].

Tirzepatide (compared to insulin degludec) has been shown to reduce intrahepatic triglycerides in type 2 diabetes [80], and may offer novel treatment options for patients with fatty liver disease (as previously described for selective GLP-1 RAs [81]). It will be important to understand how much of the effect to reduce steatosis is due to weight loss and whether there are also effects independent of this.

Outlook
Tirzepatide now is the first peptide dual agonist targeting GIP and GLP-1 receptors approved for the therapy of diabetes in the USA, Europe, and the UAE. Clinical trials employing this once-weekly injected compound impress with unprecedented effectiveness regarding glycaemic control (often resulting in normoglycaemia) and body weight reduction, in quantities that are likely to substantially change the underlying pathogenesis of type 2 diabetes [82] and have been associated with diabetes remission [83, 84]). The magnitude of the effects of tirzepatide on glycemia and weight loss opens a new era in diabetes therapy with the promise to substantially change the underlying pathogenesis of type 2 diabetes [82] and have been associated with diabetes remission [83, 84]). The magnitude of the effects of tirzepatide on glycemia and weight loss opens a new era in diabetes therapy with the promise to substantially change the underlying pathogenesis of type 2 diabetes [82] and have been associated with diabetes remission [83, 84]).

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01604-7.

Additional file 1: Figure S1. Meta-analysis of results reported from SURPASS-1 to -5 clinical trials regarding reductions in HbA1c, fasting plasma glucose concentrations, and body weight reductions (all vs. baseline). Efficacy results were analysed based on the reported efficacy estimand (calculated from data gathered while patients received their assigned randomized treatment, excluding data after discontinuing the allotted medication or after adding rescue medication. Results obtained with each dose (5, 10, or 15 mg per week) were pooled by calculating weighted mean values and pooled standard deviations. Statistical analysis: Repeated-measures analysis of variance (p-value, for the comparison of all four study arms) and post hoc Duncan’s tests to locate statistically significant differences (if overall analysis had indicated a p-value < 0.05) between any two doses of tirzepatide. Figure S2. Meta-analysis of results reported from SURPASS-1 to -5 clinical trials regarding achievement of HbA1c targets. Results obtained with each dose (5, 10, or 15 mg per week) were pooled by calculating weighted mean values and pooled standard deviations. Statistical analysis: χ² test (p-value, for the comparison of all four study arms) and post hoc Fisher’s exact tests to locate statistically significant differences (if overall analysis had indicated a p-value < 0.05) between any two doses of tirzepatide. Figure S3. Meta-analysis of results reported from SURPASS-1 to -5 clinical trials regarding discontinuation of study medications (A. overall; B. due to gastro-intestinal adverse events) and gastro-intestinal adverse events (patients reporting at least one episode of C. nausea; D. vomiting; E. diarrhoea). Results obtained with each dose (5, 10, or 15 mg per week) were pooled by calculating weighted mean values and pooled standard deviations. Statistical analysis: χ² test (p-value, for the comparison of all four study arms) and post hoc Fisher’s exact tests to locate statistically significant differences (if overall analysis had indicated a p-value < 0.05) between any two doses of tirzepatide.
Acknowledgements

We thank Laura Weilandt and Sonja Bartholomé for help with retrieving literature.

Author contributions

MAN performed the initial literature search, conducted data analyses summarizing the tirzepatide clinical trials, and wrote the initial draft manuscript. DDA added literature and substantially revised the manuscript. MAN is the guarantor who takes full responsibility for the work as a whole, including design, data analyses, and access to data. Both authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. There has not been any specific funding for preparing the present manuscript.

Availability of data and materials

The manuscript entirely reports published data. Spreadsheets with data as compiled for the present manuscript can be made available on reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

MAN has been member on advisory boards or has consulted with Boehringer Ingelheim, Eli Lilly & Co, Menarini/Berlin Chemie, Merck, Sharp & Dohme, Novo Nordisk, Regor, and Shouyi Inc./Gastherbrum. He has received grant support from Merck, Sharp & Dohme. He is member of a data monitoring and safety board for Inventiva. He has also served on the speakers’ bureau of Eli Lilly & Co, Medscape, Medical Learning Institute, Menarini/Berlin Chemie, Merck, Sharp & Dohme, Novo Nordisk, and Sun Pharmaceuticals. D.A.D. consults for Eli Lilly & Co. and Sun Pharmaceuticals.

Author details

1 Diabetes, Endocrinology and Metabolism Section, Medical Department I, Katholische Klinikum Bochum gGmbH, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791 Bochum, Germany. 2 Division of Endocrinology and Metabolism, Department of Medicine, Duke University Medical Center, Durham, NC 27701, USA.

Received: 11 July 2022 Accepted: 19 August 2022

Published online: 01 September 2022

References

1. Guyenet SJ, Schwartz MW. Clinical review: regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab. 2012;97:745–55.

2. Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257–62.

3. Day JW, Ottaway N, Patterson JT, Geffanov V, Smiley D, Gidda J, Findeisen H, Bruegger D, Drucker DJ, Chaudhary N, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5:749–57.

4. Finan B, Clemmensen C, Müller TD. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multianagonists. Mol Cell Endocrinol. 2015;419(Pt 1):42–54.

5. Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, Nauck M, Knop FK. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides. 2020;125:170183.

6. Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabet Obes Metab. 2018;20(Suppl 1):S5–21.

7. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig. 1993;91(1):301–7.

8. Mentis N, Vardari I, Kothé LD, Holst JJ, Deacon CF, Thedorakis M, Meier JJ, Nauck MA. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60:1270–6.

9. Finan B, Ma T, Ottaway N, Muller TD, Habecker RG, Heppner MM, Kirchner H, Hollard J, Hemberle J, Raventos C, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151.

10. Adriaenssens AE, Griibble FM, Reimann F. The glucagon-dependent insulinotropic polypeptide signaling axis in the central nervous system. Peptides. 2020;125:170194.

11. Zhang Q, Delesca CT, Augustin R, Bakhti M, Colloten G, Drucker DJ, Feucht- inger A, Cacerezs CG, Grandi G, Harger A, et al. The glucagon-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(833–844):e835.

12. NamKoong C, Kim MS, Jang BT, Lee YH, Choi YJ. Central adminis- tration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun. 2017;490:247–52.

13. Coskun T, Sloop KW, Loghin C, Alisna-Fernandez J, Urvia S, Bokvist KB, Cui X, Briere DA, Caberta O, Roell WC, et al. LYS3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;13:8–14.

14. Frias JP, Nauck MA, Van J, Kutter ME, Cui X, Benson C, Urvia S, Girmeno RE, Milicevic Z, Robins D, et al. Efficacy and safety of LYS3298176, a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes. a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–93.

15. Rosenstock J, Wyscham C, Frias JP, Kaneko S, Lee CJ, Fernandez Lando L, Cui X, Kuri C, Karanakis CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143–55.

16. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K. Investigators S-. tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–15.

17. Ludvik B, Giorgino F, Jodar E, Frias JP, Fernandez Lando L, Brown K, Bray R, Rodriguez A. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583–98.

18. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Azzenberg D, Wynne AG, Riesmeyer JS, Heine RJ, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.

19. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodriguez A. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327:534–45.

20. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungras S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28:591–8.

21. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exenatid-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabet Care. 2005;28:1092–100.

22. Holst JJ, Ørskov C, Vang-Nielsen O, Schwartz TW. Truncated glucagon- like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987;211:169–74.

23. Moody AJ, Thim L, Valverde I. The isolation and sequencing of human gastric inhibitory polypeptide (GIP). FEBS Lett. 1984;172:142–8.

24. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma

25. Fabbrizzi F, Schaufele N, D'Alessio DA, Defronzo RA. Somatostatin receptors: potential targets for the treatment of obesity and diabetes. Diabetes. 2012;61(Suppl 1):S85–93.
suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267:7402–5.

25. Sun B, Williard FS, Feng D, Alisina-Fernandez J, Chen Q, Vieht M, Ho JD, Showalter AD, Stutsman C, Ding L, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119.

26. Furuhata K, Kimura H, Utva S, Oura T, Ohwaki I, Imaoa T. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022;24:239–46.

27. Utva S, Quinlan T, Landry J, Martin J, Loghin C. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2021;60:1049–59.

28. Utva S, Quinlan T, Landry J, Ma X, Martin JA, Benson CT. Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2022;60(8):1049–59.

29. Frias JP, Nauck MA, Vani J, Benson C, Bray R, Cui X, Milicevic Z, Utva S, Haupt A, Robins DA. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2022;24:938–46.

30. Mil T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther. 2021;12:143–57.

31. Aroda VR, Bain SC, Canoou B, Piletic M, Rose L, Axelsson M, Rowe E, DeVries JH. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355–66.

32. Nauck MA, Meier JJ. Management of endocrine DISEASE: are all GLP-1 receptor agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–34.

33. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;64:1011–22.

34. DeVries JH, Desouza C, Bellary S, Unger J, Hansen OKH, Zacho J, Woo V. GLP-1 receptor agonists equal in the treatment of type 2 diabetes. Eur J Endocrinol. 2017;5:355–66.

35. Whysham CH, Tofe S, Sapin H, Malik R, Neff LM. Effect of once-weekly TZP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70:2545–53.

36. Costa A, Li M, Nunn N, Culiota J, Hunter J, Boudjadia MB, Valencia-Torres L, Aviello G, Hudson DJ, Snider BM, et al. Anorectic and averse effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Mol Metab. 2022;55:101407.

37. Heise T, De Vries JH, Coskun T, Utva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Dunn JP, Haupt A, et al. Tizepatide reduces appetite, energy intake, and fat mass in people with T2D (abstract). Diabetes. 2022;71(Suppl 1):1338.

38. Heise T, Mari A, DeVries JH, Utva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, et al. Effects of subcutaneous tirzepatide versus placebo on appetite and energy intake in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2022;10:418–29.

39. Samms RJ, Chrise ME, Collins KA, Pirro V, Droz BA, Holland AK, Friedrich JL, Wojnicki S, Konkol DL, Cosgrove R, et al. GLP-RA agonist mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021. https://doi.org/10.1172/JCI146353.

40. Samms RJ, Coghlan MP, Sloop KW. How May GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31:410–21.

41. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab. 2022;24(Suppl 3):1–59.

42. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) (7–36 amide) in the fasting state in healthy subjects. Acta Diabetol. 1995;32:13–6.

43. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1 (7–36 amide) infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76:912–7.

44. Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBM, Sparell Ulrich AH, Veedelf S, Sønsten S, Larning AR, Bergmann NC, et al. Separate and combined glucometabolic effects of endogenous glucose-dependent-insulinotropic peptide and glucagon-like peptide 1 in healthy individuals. Diabetes. 2019;68:908–17.

45. Gasbjerg LS, Helsted MM, Hartmann B, Sparell Ulrich AH, Veedelf S, Sønsten S, Larning AR, Bergmann NC, Christensen MB, Vlbolll T, et al. GIP and GLP-1 receptor antagonism during a meal in healthy individuals. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/ dgz175.

46. Nauck MA, Kleinie N, Ørskov C, Holst JJ, Wills B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–4.

47. Vlbolll T, Krapuj T, Madisbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–9.

48. Nauck MA, Heimesaat MA, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during...
hypersulinaemic, stepped hypoglycaemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–46.

61. Christensen M, Vedtofte L, Holst JJ, Vilbort T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60:3103–9.

62. Christensen MB, Calanna S, Holst JJ, Vilbort T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab. 2014;99(3):E418-426.

63. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide-1 (7–36) amide on glucagon effect and insulin action in people with type 2 diabetes. Diabetes. 2000;49(4):611–7.

64. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1) (7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81(1):327–32.

65. Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM. Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes. Diabetes. 2009;58:1342–9.

66. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide-1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–30.

67. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:151–20.

68. Bergmann NC, Lund A, Gasber JS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019;62:665–73.

69. Verdich C, Flint A, Gutzwiller JP, Næslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382–9.

70. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epiphemenon of impaired beta-cell function? Diabetes. 2010;59:1117–25.

71. Højbærg PV, Vilbort T, Rabol R, Knop FK, Bache M, Karup T, Holst JJ, Madsbad S. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2006;49:199–205.

72. Pamir N, Lynn FC, Buchan AM, Ehres J, Hinke SA, Pospísilik JA, Miyakawa K, Yamada Y, Seino Y, McIntosh CH, et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinversus axis. Am J Physiol. 2003;284:E931-939.

73. Pederson RA, Sakunaranja M, McIntosh CH, Scroccia LA, Flamenz D, Schult F, Drucker DJ, Wheeler MB. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes. 1998;47:1046–52.

74. Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 2019;30(987–996):e986.

75. Killion EA, Lu SC, Fort M, Yamada Y, Veniant MM, Lloyd DJ. Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists antagonists. Endocr Rev. 2020. https://doi.org/10.1210/endrev/bnz002.

76. Jastreboff AM, Aронний LJ, Ahmad NN, Whatson S, Connery L, Alves B, Kyosue A, Zhang S, Liu B, Bunck MC, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. https://doi.org/10.1056/NEJMoa2206038.

77. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758–67.

78. Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MIR): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406.

79. Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33:424–42.

80. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399:394–405.

81. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McComble L, Peters C, Zhyzhneykaya S, Al-Mrabeah A, Hollingsworth KG, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391:541–51.

82. Heimbürger SM, Bergmann NC, Augustin R, Gasber JS, Christensen MB, Knop FK. Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. Peptides. 2020;125:170174.

83. Ussher JR, Campbell JE, Mulvihill EE, Baggio LL, Bates HE, McLean BA, Gopal K, Capozi M, Yusta B, Cao X, et al. Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction. Cell Metab. 2018;27(450–460):e456.

84. Juic A, Nilsson PM, Atabaki-Pasdar N, Diederan A, Tuomi T, Franks PW, Holst JJ, Torekov SS, Ravassa S, Diez J, et al. Glucose-dependent insulinotropic peptide in the high-normal range ss associated with increased carotid intima-media thickness. Diabetes Care. 2021;44:224–30.

85. Juic A, Atabaki-Pasdar N, Nilsson PM, Almgren P, Hakaste L, Tuomi T, Berglund LM, Franks PW, Holst JJ, Prasad RB, et al. Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia. 2020;63:1043–54.

86. Karhunen V, Daghlis J, Zubbr V, Vujkovic M, Olsen AK, Knudsen LB, Haynes WG, Howson JMW, Gill D. Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. Diabetologia. 2021;64:2773–8.

87. Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluo et al. Multi-agonists: a new paradigm in metabolic pharmacology. J Intern Med. 2018;284:581–602.

88. Gastaldelli A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in metabolic dysfunction-associated fatty liver disease. A 54-week randomized phase 2b study. Diabet Care. 2021;44:1433–42.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.